Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 76 Gross Margin % is 34.97% as of Dec. 2025, which is 4% above its 10-year median of 33.70. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, Level Biotechnology ranks worse than 73.12% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Level Biotechnology had a gross margin of 34.97% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Level Biotechnology Gross Margin % Related Terms
Level Biotechnology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Level Biotechnology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Level Biotechnology (ROCO:3118) has a Gross Margin % of 34.97% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Level Biotechnology and its competitors. This is near median its historical median of 33.70. Over the past decade, Level Biotechnology's Gross Margin % has ranged from 29.49 to 37.74. According to the industry distribution chart, Level Biotechnology ranks #536 out of 733 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Level Biotechnology's Gross Margin % too high?
Level Biotechnology's current Gross Margin % of 34.97% is near median its 10-year median of 33.70. Over the past 10 years, this metric has ranged from a low of 29.49 to a high of 37.74. The Biotechnology industry median Gross Margin % is 60.91. Level Biotechnology's value of 34.97% is 42.6% below this industry median. Based on the distribution chart, Level Biotechnology ranks #536 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #536 out of 733 companies for Gross Margin %. This places Level Biotechnology in the lower half of its industry. The industry median Gross Margin % is 60.91. Level Biotechnology's value of 34.97% is 42.6% below this benchmark. Historically, Level Biotechnology's own Gross Margin % has ranged from 29.49 to 37.74 over the past decade. While the company's 10-year median is 33.70 vs. the industry median of 60.91, Level Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current Gross Margin % of 34.97% is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current Gross Margin % is 34.97%, which is near median its own 10-year median of 33.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current Gross Margin % is 34.97%, which is near median its 10-year median of 33.70 and 42.6% below the Biotechnology industry median of 60.91. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Gross Margin % is 34.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
Gross Margin %: 34.97% (near median its 10-year median of 33.70)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
Industry Position: 42.6% below the Biotechnology median (#536 of 733)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
